Investment
Features
FeesSafety
Academy
More
Pluang+

CVS Health seen as a strong buy after recent selloff with attractive valuation and growth prospects.

Analyst Insights
24 Aug 2026
Seeking Alpha
View Source
Bullish
pluang ai news

CVS Health's integrated healthcare model across insurance, pharmacy, and clinical care supports its long-term margin recovery and revenue growth. The recent stock selloff has lowered its price-to-earnings ratio to 11.78, making it an attractive buy with potential capital gains to a target price of $129.90 and a 2.84% dividend yield. Despite some risks from membership attrition expected by 2027, CVS's strong management and strategy position it well amid rising medical costs. Investors may find a better entry point near the 200-day moving average, but overall CVS remains a compelling investment opportunity.

More News (CVS)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App